Investment Rating - The industry investment rating is "Outperform the Market" with an expected relative increase of over 10% in the next six months [25]. Core Insights - The fund allocation ratio for the beauty and personal care industry decreased in Q3 2025, with a total market capitalization of 284.799 billion yuan, reflecting a 2.79% increase from Q2 2025. The fund's total holdings in the beauty and personal care sector amounted to 6.796 billion yuan, resulting in a fund allocation ratio of 0.20%, which is a decrease of 0.12 percentage points from Q2 2025, indicating a continued underweight position [2][11]. - The medical beauty sub-sector is currently in an overweight position, while personal care and cosmetics are underweight. The fund allocation ratio for personal care products was 0.04% in Q3 2025, down 0.04 percentage points from the previous quarter. The cosmetics sector also saw a decline, maintaining a fund allocation ratio of 0.04% in Q3 2025, down 0.02 percentage points [3][16]. - The top three stocks by fund holding in Q3 2025 are Jinbo Biological, Aimeike, and Baiya Shares, with a total holding ratio of 0.07%, which is a decrease of 0.04 percentage points from Q2 2025 [4][18]. Summary by Sections Industry Overview - In Q3 2025, the beauty and personal care industry fund allocation ratio decreased to 0.20%, with an underweight ratio of -0.09%, indicating a continued low allocation [2][11]. Sub-sector Analysis - Medical Beauty: The fund allocation ratio peaked at 0.53% in Q4 2022 but has since declined to 0.12% in Q3 2025, with an overweight ratio of 0.03% in Q2 2025 [3][16]. - Personal Care: The fund allocation ratio was at a historical low from Q3 2021 to Q3 2022, with a slight recovery post-Q4 2022. The current ratio is 0.04%, indicating a shift from positive to negative overweight [3][16]. - Cosmetics: The fund allocation ratio has been declining since Q3 2022, currently at 0.04%, with an overweight ratio of -0.09% [3][16]. Stock Holdings - The top three stocks in the beauty and personal care sector by fund holding in Q3 2025 are Jinbo Biological (0.0254%), Aimeike (0.0195%), and Baiya Shares (0.0051%), all showing a decline in holding ratios compared to Q2 2025 [4][21]. Investment Recommendations - The report suggests focusing on cosmetics and medical beauty sectors due to significant demand potential in the long term, driven by the "beauty economy." It also highlights the importance of compliance and strong R&D capabilities in personal care products [5][24].

Core Viewpoint - The personal care products sector experienced a decline of 0.3% on November 6, with Runben Co., Ltd. leading the drop. Meanwhile, the Shanghai Composite Index rose by 0.97% to close at 4007.76, and the Shenzhen Component Index increased by 1.73% to 13452.42 [1]. Group 1: Market Performance - The personal care products sector saw a mixed performance among individual stocks, with notable gainers including Beijiajie (+1.53%) and Liangmianjin (+1.08%), while Runben Co., Ltd. led the decline at -1.86% [1][2]. - The trading volume for Beijiajie was 21,300 hands, with a transaction value of approximately 65.74 million yuan, while Runben Co., Ltd. had a trading volume of 41,700 hands and a transaction value of about 108 million yuan [1][2]. Group 2: Capital Flow - The personal care products sector experienced a net outflow of 23.85 million yuan from institutional investors, while retail investors saw a net inflow of 15.48 million yuan [2]. - Among individual stocks, Liangmianjin attracted a net inflow of 11.18 million yuan from institutional investors, while Runben Co., Ltd. faced a net outflow of 1.36 million yuan [3].

Core Viewpoint - The stock of Steady Medical (300888) has shown a slight increase in price, with significant fluctuations in capital flow, indicating mixed investor sentiment and potential growth in the healthcare sector [1][2]. Financial Performance - For the first three quarters of 2025, Steady Medical reported a main business revenue of 7.897 billion yuan, a year-on-year increase of 30.1% [3] - The net profit attributable to shareholders was 732 million yuan, up 32.36% year-on-year [3] - The third quarter alone saw a main business revenue of 2.601 billion yuan, a 27.71% increase year-on-year, and a net profit of 240 million yuan, up 42.11% year-on-year [3] - The company’s gross profit margin stands at 48.32%, which is higher than the industry average of 42.35% [3] Market Position - Steady Medical has a total market capitalization of 23.619 billion yuan, ranking 4th in the beauty and personal care industry [3] - The company has a net asset value of 12.263 billion yuan, ranking 1st in the industry [3] - The price-to-earnings ratio (P/E) is 24.2, which is lower than the industry average of 38.73, indicating a potentially undervalued stock [3] Capital Flow Analysis - On November 5, 2025, the stock experienced a net outflow of 11.2619 million yuan from main funds, accounting for 5.81% of the total transaction volume [1][2] - Retail investors showed a net inflow of 5.3821 million yuan, representing 2.78% of the total transaction volume [1][2] - Over the past five days, the stock has seen varying capital flows, with significant fluctuations in both institutional and retail investor activities [2] Analyst Ratings - In the last 90 days, 21 institutions have rated the stock, with 17 buy ratings and 4 hold ratings [4] - The average target price set by institutions is 5.383 billion yuan, indicating a potential upside from the current trading price [4]

Group 1 - The core viewpoint of the news is the initiation of large-scale clinical trials for gene-edited pig kidneys for human transplantation, marking a significant advancement in biotechnology and organ transplantation [1] - The first clinical trial was completed at NYU Langone Medical Center, approved by the FDA, aiming to evaluate the safety and efficacy of gene-edited pig kidneys for patients with end-stage kidney disease [1] - Global advancements in gene editing technology have been reported, including successful transplantation of gene-edited pig lungs in China and new treatment approaches for Down syndrome in Japan [1] Group 2 - Huazhong Securities highlights that breakthroughs in gene editing technology have significantly lowered the technical barriers for genetic modification, enabling large-scale industrial production of drugs [2] - In the A-share market, there are 22 listed companies with gene editing technology reserves, with mixed performance in stock prices; only 7 out of 22 companies saw gains on November 5 [4] - Among gene editing concept stocks, Shuanglu Pharmaceutical reported the highest net profit of 141 million yuan in the first three quarters, while Mengcao Ecological achieved a year-on-year profit increase of 48.73% [5][6] Group 3 - Eight gene editing concept stocks received attention from five or more institutions, with companies like Sturdy Medical and Huaxi Biological leading in institutional ratings [7] - Sturdy Medical announced a collaboration with Huazhong Agricultural University to establish a cotton research institute, focusing on gene editing and hybridization techniques for cotton seed improvement [7]

Group 1 - The core point of the news is the initiation of large-scale clinical trials for gene-edited pig kidneys for human transplantation, marking a significant breakthrough in gene editing technology [1] - The trials are approved by the FDA and aim to systematically evaluate the safety and efficacy of gene-edited pig kidneys for patients with end-stage kidney disease [1] - There have been multiple advancements in gene editing technology globally, including successful transplants of gene-edited organs and new treatment approaches for genetic disorders [1] Group 2 - Huazhong Securities notes that breakthroughs in gene editing technology have significantly lowered the technical barriers for genetic modification, enabling large-scale industrial production and reducing drug production costs [2] - A total of 22 listed companies in the A-share market have gene editing technology reserves, with several companies reporting profitability in their third-quarter results [3] - Notable companies include Shuanglu Pharmaceutical, which reported a net profit of 141 million yuan, and Mengcao Ecological, which saw a 48.73% year-on-year increase in net profit [3][4] Group 3 - Companies like Wanjian Medical are collaborating with research institutions to develop cotton varieties using gene editing technology, indicating the application of gene editing beyond human health [5] - The number of institutional ratings for gene editing concept stocks shows significant interest, with companies like Wanjian Medical and Huaxi Biological receiving the highest number of ratings [6]

Key Insights - The report highlights a rebound in the electrolyte industry, with significant growth potential in fluorinated liquids, particularly for the company Xinzhou Bang, which reported a revenue of 6.616 billion yuan for the first three quarters of 2025, a year-on-year increase of 16.75% [6][10] - The company achieved a net profit of 748 million yuan, up 6.64% year-on-year, with a sales gross margin of 24.51%, reflecting a decline of 2.58 percentage points [6][10] - The report indicates that the company is well-positioned to benefit from the recovery in the electrolyte market, driven by rising prices of lithium hexafluorophosphate and improved operational efficiency [10][11] Group 1: Xinzhou Bang (Battery) - The company reported a revenue of 2.368 billion yuan in Q3 2025, a year-on-year increase of 13.60% and a quarter-on-quarter increase of 5.45% [7] - The net profit for Q3 2025 was 264 million yuan, down 7.51% year-on-year but up 4.03% quarter-on-quarter, indicating a mixed performance [7][8] - The company is focusing on optimizing its product structure and enhancing operational efficiency, with a stable growth trajectory in its organic fluorine chemicals and electronic information chemicals [9][10] Group 2: Weijian Medical (Personal Care Products) - The company achieved a revenue of 7.897 billion yuan in the first three quarters of 2025, a year-on-year increase of 30.10%, with a net profit of 732 million yuan, up 32.36% [13][14] - The medical segment saw a revenue increase of 44.4%, driven by strong growth in surgical consumables and high-end dressings [14] - The consumer segment also performed well, with a revenue of 4.01 billion yuan, up 19.1%, led by significant growth in the sales of sanitary products [15] Group 3: Longqi Technology (Consumer Electronics) - The company reported a revenue of 31.332 billion yuan for the first three quarters of 2025, a year-on-year decrease of 10.28%, but a net profit increase of 17.74% [21] - In Q3 2025, the revenue was 11.424 billion yuan, down 9.62% year-on-year, while the net profit increased by 64.46% [22] - The company is expanding its product portfolio under the "1+2+X" strategy, focusing on smart devices and automotive electronics [23][24] Group 4: Minxin Technology (Semiconductors) - The company reported a revenue of 464 million yuan in the first three quarters of 2025, a year-on-year increase of 37.73%, with a gross margin of 30.28% [25][26] - In Q3 2025, the revenue was 160 million yuan, up 21.9% year-on-year, indicating strong demand for pressure and inertial sensors [25][27] - The company is well-positioned to benefit from the growth of MEMS sensors in the AI era, with a diverse product matrix [26][28] Group 5: Yingly Technology (General Equipment) - The company reported a revenue of 2.121 billion yuan in the first three quarters of 2025, a year-on-year increase of 11.02%, with a net profit of 294 million yuan, up 29.59% [35][36] - The company is expanding its processing and coating capabilities in the blade and casing industry, which is expected to enhance its production capacity [37] - The gross margin for Q3 2025 was 38.03%, reflecting a significant improvement in profitability [38] Group 6: Weichai Power (Automotive Parts) - The company reported a revenue of 170.57 billion yuan for the first three quarters of 2025, a year-on-year increase of 5.3%, with a net profit of 8.88 billion yuan, up 5.7% [44] - In Q3 2025, the revenue was 57.42 billion yuan, up 16.1% year-on-year, driven by strong demand in the heavy truck sector [44] - The company is benefiting from the recovery in the heavy truck market, with significant growth in natural gas and electric vehicle sales [44]

Group 1: Market Overview - The Hong Kong stock market performed poorly in October 2025, with the Hang Seng Index declining by 3.5% and the Hang Seng Technology Index falling by 8.6% [5] - The average daily trading volume in October was HKD 211.3 billion, a decrease of 16.6% compared to September 2025 [5] - Value sectors outperformed growth sectors, with coal, oil and petrochemicals, electricity, and utilities leading the gains [5] Group 2: Fund Flow Analysis - Southbound capital saw a total net inflow of HKD 925 billion in October 2025, with a cumulative net inflow of HKD 1.26 trillion for the year, marking a 156% increase compared to 2024 [6] - The market value proportions of southbound funds, foreign capital, domestic capital, and Hong Kong capital as of October 28, 2025, were 21.49%, 58.86%, 12.66%, and 6.99% respectively [6] Group 3: Industry Insights Consumer Goods - The oral care market in China reached a retail scale of CNY 30.2 billion in 2023, with a growth rate of 0.2% year-on-year [16] - The sanitary napkin market is projected to grow to CNY 105 billion in 2024, with a year-on-year growth of 2.9% [17] - The global wet wipes market is expected to reach USD 18.4 billion in 2024, growing at 2.7% year-on-year [17] Military Industry - The demand for titanium materials in aerospace and naval applications is expected to reach 49,000 tons by 2027 [22] - The titanium material usage in the shipbuilding sector is projected to grow significantly, driven by national strategies for marine development [24] - Beneficiary stocks in the titanium sector include BaoTi Co., West Superconducting, and West Materials [26] Automotive Industry - SAIC Group reported a revenue of CNY 468.99 billion for the first three quarters of 2025, a year-on-year increase of 9.0% [31] - The company’s Q3 sales volume reached 1.1407 million vehicles, reflecting a 38.7% increase year-on-year [32] - The company is focusing on enhancing decision-making efficiency and optimizing resource allocation through the establishment of a new passenger vehicle division [33] Nonferrous Metals - Yun Aluminum Co. achieved a revenue of CNY 44.072 billion in the first three quarters of 2025, with a year-on-year increase of 12.47% [35] - The company’s net profit for Q3 was CNY 1.63 billion, a year-on-year increase of 25.31% [35] - The company plans to increase its dividend payout ratio, enhancing investor confidence [38] Semiconductor Testing - The company reported a revenue of CNY 737 million for the first three quarters of 2025, a year-on-year increase of 44.01% [40] - The company has successfully developed the first domestic open X-ray source, marking a significant advancement in high-end detection equipment [41] - The acquisition of SSTI is expected to enhance the company's performance in the high-end semiconductor testing equipment sector [42]

Core Insights - The stock of Steady Medical (300888) closed at 40.27 yuan on November 4, 2025, down 1.56% with a trading volume of 53,900 hands and a turnover of 217 million yuan [1][2] Financial Performance - For the first three quarters of 2025, Steady Medical reported a main revenue of 7.897 billion yuan, a year-on-year increase of 30.1% [3] - The net profit attributable to shareholders was 732 million yuan, up 32.36% year-on-year, while the net profit excluding non-recurring items was 679 million yuan, increasing by 43.93% [3] - In Q3 2025, the company achieved a single-quarter main revenue of 2.601 billion yuan, a year-on-year increase of 27.71%, and a net profit of 240 million yuan, up 42.11% year-on-year [3] Market Position - Steady Medical's total market capitalization is 23.45 billion yuan, ranking 4th in the beauty and personal care industry [3] - The company has a net asset of 12.263 billion yuan, ranking 1st in the industry [3] - The price-to-earnings ratio (P/E) is 24.03, which is lower than the industry average of 39.13, ranking 2nd [3] Investment Sentiment - In the last 90 days, 20 institutions rated the stock, with 16 buy ratings and 4 hold ratings, and the average target price set by institutions is 54.09 yuan [4]

Investment Rating - The report maintains an "Overweight" rating for the industry, with a focus on new consumption sectors such as beauty care, IP derivatives, and gold jewelry [5][32]. Core Insights - The report highlights the recent tax policy changes regarding gold, which exempts value-added tax for standard gold transactions, potentially boosting market activity [3][22]. - The beauty care sector shows mixed performance, with some companies reporting significant revenue growth while others face declines [4][25]. - The report emphasizes the importance of domestic brands in the beauty market, with notable rankings in the Douyin beauty list indicating a shift towards local products [22][23]. Market Performance - During the week of October 27 to October 31, 2025, the retail trade, social services, and beauty care sectors experienced changes of +1.63%, +0.45%, and -2.21% respectively, ranking 8th, 17th, and 30th among 31 primary industries [13][15]. - The cosmetics sector faced a decline of -2.57%, while segments like trade and e-commerce performed well with increases of +3.44% and +2.97% [15][18]. Key Company Announcements - Shanghai Jahwa reported a revenue of 4.961 billion yuan for the first three quarters of 2025, a year-on-year increase of 10.8%, with a net profit growth of 149.1% [25]. - Proya Cosmetics achieved a revenue of 7.098 billion yuan, reflecting a modest growth of 1.89% [25]. - The opening of Pop Mart's first store in the Middle East marks a significant expansion for the brand [29]. Investment Recommendations - The report suggests focusing on companies such as Shiseido, Giant Bio, Marubi, Runben, Proya, Chaohongji, and Furuida as potential investment targets within the recommended sectors [5][32].

Market Overview - The personal care products sector experienced a decline of 0.95% on November 4, with Dengkang Oral Care leading the drop [1] - The Shanghai Composite Index closed at 3960.19, down 0.41%, while the Shenzhen Component Index closed at 13175.22, down 1.71% [1] Stock Performance - Notable stock performances include: - Liangmian Needle (600249) rose by 1.72% to close at 6.49, with a trading volume of 321,100 shares and a turnover of 210 million yuan [1] - Zhongshun Jiesang (002511) increased by 0.25% to 8.09, with a trading volume of 144,000 shares [1] - Dengkang Oral Care (001328) fell by 3.17% to 36.65, with a trading volume of 21,900 shares and a turnover of approximately 80.70 million yuan [2] Capital Flow - The personal care products sector saw a net outflow of 41.58 million yuan from institutional investors and 41.59 million yuan from speculative funds, while retail investors had a net inflow of 83.17 million yuan [2] - Detailed capital flow for selected stocks indicates: - Yanjing Co. (300658) had a net inflow of over 9.99 million yuan from institutional investors [3] - Dengkang Oral Care (001328) experienced a net outflow of 2.68 million yuan from institutional investors [3] - The overall trend shows a mixed response from different investor categories, with retail investors showing a positive net inflow across several stocks [3]